The clinical trial conducted by the University of Sao Paulo General Hospital evaluated the efficacy of Methotrexate (MTX) in adult patients with moderate to severe Atopic Dermatitis (AD). Given the chronic nature of AD and the limited treatment options available for refractory cases, successful outcomes could position MTX as a viable alternative therapy in a market that is increasingly focused on innovative treatments for dermatological conditions. The trial's focus on cytokine modulation may also provide insights into the broader therapeutic applications of MTX in inflammatory diseases, potentially enhancing its marketability. Competitive analysis reveals that while several biologics are currently available for AD, the need for effective systemic therapies remains, particularly for patients unresponsive to conventional treatments. This trial could inform future development strategies and partnerships in the dermatology space.